Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 862 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: hRPC Clear all
Completed Phase 1 Interventional

Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer

NCT01823978
View directory record Official record
Conditions
Castrate Resistent Prostate Cancer
Interventions
BPX-201 vaccine plus AP1903
Biological
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Birmingham, Alabama • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 24, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

NCT02985957
View directory record Official record
Conditions
Prostate Cancer
Interventions
Nivolumab, Ipilimumab, Cabazitaxel, Prednisone
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
15
States / cities
Tucson, Arizona • Marietta, Georgia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 24, 2026, 4:57 AM EDT
Terminated Phase 1 Interventional

A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity

NCT01262664
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prohibitin-TP01
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 24, 2026, 4:57 AM EDT
Completed Phase 2 Interventional

Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer

NCT00448409
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
TroVax, GM-CSF
Biological · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 24, 2026, 4:57 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

NCT03419234
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Abiraterone Acetate, Androgen deprivation therapy, Cabazitaxel, Prednisone
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
665
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 437 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 24, 2026, 4:57 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

NCT03706365
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abemaciclib, Placebo, Abiraterone acetate, Prednisone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 24, 2026, 4:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

NCT01848067
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
Alisertib, Abiraterone acetate, Prednisone
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 24, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa

NCT04604899
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
human retinal progenitor cells
Biological
Lead sponsor
jCyte, Inc
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Irvine, California • Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 24, 2026, 4:57 AM EDT
Terminated Phase 2 Interventional Results available

Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy

NCT03042312
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
177Lu-PSMA-617
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 24, 2026, 4:57 AM EDT
Active, not recruiting Phase 3 Interventional Results available

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT02257736
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, Abiraterone acetate, Prednisone, Placebo
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
46
States / cities
Phoenix, Arizona • La Mesa, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 24, 2026, 4:57 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

NCT02111577
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DCVAC/PCa, Placebo
Biological
Lead sponsor
SOTIO a.s.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
58
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 24, 2026, 4:57 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT03575819
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
FOR46
Drug
Lead sponsor
Fortis Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 24, 2026, 4:57 AM EDT
Terminated Phase 1Phase 2 Interventional

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

NCT05075577
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide, EPI-7386 with Enzalutamide
Drug
Lead sponsor
ESSA Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Tucson, Arizona • Port Saint Lucie, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 24, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

NCT01750398
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
Testosterone cypionate, Goserelin, Leuprolide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 24, 2026, 4:57 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

NCT02522715
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
Interventions
Cabazitaxel, Enzalutamide, Laboratory Biomarker Analysis, Pharmacological Study, Prednisone
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
3
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 24, 2026, 4:57 AM EDT
Terminated Phase 1 Interventional Results available

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

NCT03478904
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide Liquid, Enzalutamide Capsule
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 24, 2026, 4:57 AM EDT
Completed Not applicable Interventional

Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine in Prostate Cancer Patients

NCT00139204
View directory record Official record
Conditions
Prostate Cancer
Interventions
C11 Methionine PET scan
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2009 · Synced Oct 24, 2026, 4:57 AM EDT
Completed No phase listed Observational

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).

NCT03896984
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
Radium-223 (Xofigo, BAY88-8223), Abiraterone, Enzalutamide
Drug
Lead sponsor
Bayer
Industry
Eligibility
Male only
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 24, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

NCT01534052
View directory record Official record
Conditions
Castration-Resistant Prostate Cancer (CRPC)
Interventions
Enzalutamide
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
4
States / cities
Aurora, Colorado • Chicago, Illinois • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 24, 2026, 4:57 AM EDT
Terminated Phase 1 Interventional

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT01913015
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
abiraterone acetate, dietary intervention, pharmacological study, questionnaire administration, laboratory biomarker analysis
Drug · Dietary Supplement · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 24, 2026, 4:57 AM EDT
Recruiting Phase 1 Interventional

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

NCT06826768
View directory record Official record
Conditions
Prostate Cancer
Interventions
REGN5678, Cemiplimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 24, 2026, 4:57 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma

NCT06567314
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
Ivonescimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 24, 2026, 4:57 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

NCT03724747
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
BAY2315497 Injection, Darolutamide(BAY1841788)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
New Orleans, Louisiana • Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Oct 24, 2026, 4:57 AM EDT
Not listed Phase 1Phase 2 Interventional

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application

NCT05458544
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
[177Lu]Ludotadipep 3.7 GBq
Drug
Lead sponsor
FutureChem
Industry
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Towson, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 24, 2026, 4:57 AM EDT